SCHEDULE: Farallon Capital Discloses 5.5% Stake in BridgeBio Pharma

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 5.5% of BridgeBio Pharma, Inc.'s common stock as of June 30, 2026.

Summary

• Farallon Capital Management, L.L.C. and related entities (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of 10,743,063 shares of BridgeBio Pharma, Inc. common stock.
• This represents 5.5% of the class of securities outstanding as of June 30, 2026.
• The filing is an amendment, suggesting a change in their ownership position or a routine update.
• The shares are held across various Farallon Funds, with Farallon Capital Management, L.L.C. acting as the investment manager.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding BridgeBio Pharma's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and hedge funds like Farallon Capital when they acquire a significant stake in a public company. This filing indicates Farallon's investment interest in BridgeBio Pharma, a biotechnology company.

Stakeholder Impact

• Shareholders of BridgeBio Pharma may see this as a sign of institutional confidence, potentially influencing market perception.
• The increased stake by a significant investment manager like Farallon Capital could lead to increased trading volume and liquidity for the stock.

Key Dates

Keywords

BridgeBio Pharma, Farallon Capital, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Equity Stake